Quality evidence is needed to support a new Medicare Part D medication therapy management (MTM) program performance measure, prompting a scoping review on MTM services and associated outcomes.
TORONTO, Sept. 14, 2023 /PRNewswire/ - Black Swan Graphene Inc. (SWAN:CA) (OTCQB: BSWGF) (Frankfurt: R96) is pleased to announce the results of the scoping study for its large scale Québec facility ...
Tanbreez scoping study highlights a pre-tax NPV of US$2.4-3.0 billion at 10% and 8% discount rate and IRR of 162%, mine life of 19 years Results present the viability of the Greenland project as a ...
ADELAIDE, AU / ACCESS Newswire / February 23, 2025 / Barton Gold Holdings Limited (ASX:BGD)(FRA:BGD3)(OTCQB:BGDFF) (Barton or Company) is pleased to provide a progress update for ongoing studies at ...
Should you have feedback on this article, please complete the fields below. Please indicate if your feedback is in the form of a letter to the editor that you wish to have published. If so, please be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results